Allianz SE grew its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 17.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 94,064 shares of the company’s stock after buying an additional 14,078 shares during the period. Allianz SE’s holdings in AstraZeneca were worth $15,345,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Roxbury Financial LLC acquired a new position in shares of AstraZeneca in the second quarter valued at about $29,000. Laurel Wealth Advisors LLC bought a new position in AstraZeneca during the third quarter worth about $30,000. GK Wealth Management LLC acquired a new stake in AstraZeneca in the 3rd quarter worth about $31,000. Lynch Investment Planning LLC acquired a new stake in AstraZeneca in the 3rd quarter worth about $32,000. Finally, Resources Management Corp CT ADV acquired a new stake in AstraZeneca in the 1st quarter worth about $35,000. Institutional investors and hedge funds own 20.35% of the company’s stock.
Wall Street Analysts Forecast Growth
AZN has been the subject of a number of recent analyst reports. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, October 6th. Zacks Research upgraded AstraZeneca from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 13th. Nordea Equity Research upgraded AstraZeneca from a “sell” rating to a “buy” rating in a research note on Tuesday, October 13th. Royal Bank Of Canada started coverage on shares of AstraZeneca in a research note on Tuesday, September 8th. They issued an “outperform” rating on the stock. Finally, Deutsche Bank raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $206.67.
AstraZeneca Stock Performance
Shares of NYSE AZN opened at $174.20 on Friday. AstraZeneca Plc has a 52-week low of $153.41 and a 52-week high of $212.71. The company has a market cap of $270.17 billion, a PE ratio of 24.64, a PEG ratio of 1.43 and a beta of 0.24. The company has a quick ratio of 0.79, a current ratio of 1.01 and a debt-to-equity ratio of 0.51. The firm’s 50-day moving average price is $170.72 and its 200-day moving average price is $180.02.
AstraZeneca (NYSE:AZN – Get Free Report) last posted its quarterly earnings data on Saturday, October 31st. The company reported $2.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.60 by $0.19. The company had revenue of $16.21 billion for the quarter, compared to the consensus estimate of $16 billion. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The firm’s revenue was up 6.5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.38 earnings per share. As a group, analysts anticipate that AstraZeneca Plc will post 10.22 EPS for the current year.
AstraZeneca Profile
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Featured Stories
- Five stocks we like better than AstraZeneca
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
